Award
National Cancer Institute 4R01CA283317-03
Determinants of toxicity and response to immune checkpoint blockade through integrative profiling of T cell clonal dynamics and plasma cell-free DNA
Recipient
Mayo Clinic Rochester
Award Amount
$1,995,425.00
Ceiling
$1,995,425.00
Awarded
June 30, 2026
Identifier
4R01CA283317-03
This award funds research to understand and predict immune-related toxicities and responses in melanoma patients treated with immune checkpoint inhibitors using advanced profiling and machine learning techniques.
Description
The project involves high-dimensional profiling, machine learning, liquid biopsy, and immune cell analysis to predict and understand immune-related toxicities and responses in melanoma patients. It aims to develop liquid biopsy biomarkers for personalized immunotherapy, improving safety and efficacy.